TMCnet News
Exosome Diagnostics Announces Early Access Program for "Shahky™" - Exosome Protein Interrogation InstrumentExosome Diagnostics, Inc. announced today that it has launched its Early Access Program for its point of care protein biomarker liquid biopsy instrument. The Shahky™ instrument is the world's first system for exosome specific protein analysis. By targeting disease specific exosomes and removing non-relevant proteins, the signal to noise ratio is significantly superior to that of commercially available technologies. This enables rapid development of definitive disease specific protein biomarker signatures from any biofluid, including blood, cerebrospinal fluid, plasma, serum, urine, saliva, and ascites fluid. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170203005338/en/ World's first point of care liquid biopsy instrument for exosomal protein capture and analysis. (Photo: Business Wire) The specifications of the instrument are as follows:
"The Shahky instrument complements the company's Exolution™ platform for nucleic acid analysis. Shahky provides a decentralized business model while allowing the company to be analyte agnostic in terms of biomarker interrogation," stated John Boyce, President and CEO of Exosome Diagnostics. "Depending on the disease state and target, the combination of cell free DNA plus exosomal RNA in one reaction may the best approach, while exosomal proteins may be superior in other instances," Boyce continued. "Exosome now has the full range of analytes covered with its highly sensitive technology, to call blood - the new tissue." About Exosome Diagnostics: Exosome Diagnostics is a privately held company focused on developing and commercializing revolutionary biofluid-based diagnostics to deliver personalized precision healthcare that improves lives. The company's novel exosome-based technology platform, ExoLution™, can yield comprehensive and dynamic molecular insights to transform how cancer and other serious diseases are diagnosed, treated and monitored. Visit www.exosomedx.com to learn more. ExoDx is a registered trademark of Exosome Diagnostics, Inc. Exosome Diagnostics and ExoLution are unregistered trademarks of Exosome Diagnostics, Inc.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170203005338/en/ |